Familial HLH is a congenital disease with an impaired immunomodulation resulted from autosomal or X-linked recessive gene defect; the presentation of the symptom is found commonly in infants during the 1 st year of life. It is a congenital disorder with defects in immunomodulation. [4] While Epstein-Barr virus (EBV) infection is a well-known trigger for both primary and secondary HLH, it plays a prevailing role to induce secondary HLH onset. [5, 6] Other than the EBV-associated secondary HLH (EBV-sHLH), the main subtype of secondary HLH, infections caused by other agents such as cytomegalovirus (CMV) or herpes simplex virus (HSV), could also present HLH symptoms such as leukemia, lymphoma, Langerhans cell histiocytosis (LCH), and autoimmune or autoinflammatory disorders. [7, 8] HLH results in a multisystem impairment and infiltration of inflammatory cells in relative tissues or organs, such as spleen, liver, bone marrow, and central nervous system (CNS), leading to a series of clinical presentations. [9] [10] [11] CNS symptoms are one of the clinical manifestations frequently found in HLH patients. It was previously reported that CNS involvement of HLH children in Korea was associated with poor outcome. [12] In a study on patients with HLH in China, it was reported that 46.7% (20/43) of all investigated patients had CNS involvement. [13] However, the incidence and prognosis of CNS involvement in different kinds of HLH in Chinese children have not been investigated.
To explore this question, we retrospectively analyzed the clinical data of 179 Chinese children diagnosed with HLH at Beijing Children's Hospital and compared their different CNS involvement and outcomes in FHL, EBV-sHLH, and other sHLH.
Methods

Ethical approval
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Children's Hospital (No. 2018-k-47). As a retrospective study, this study was exempt from informed patients' consent.
Patients
A total of 179 children were diagnosed as HLH at our center between January 2010 and December 2015. Diagnosis and treatment were based on the HLH-2004 protocol. [14] The median follow-up time is 3 years (until March 31, 2017, 17 failed to follow-up). Nineteen cases were diagnosed as FHL based on the fact that homozygous or compound heterozygous mutations were found in HLH-related genes. Because EBV-sHLH is regarded as an important subtype of secondary HLH, 97 EBV-sHLH cases were selected as another group. Additional 63 secondary HLH cases were defined as other sHLH. Therefore, we distributed the total cases into three groups: FHL, EBV-sHLH, and other sHLH.
Central nervous system involvement
HLH patients with one or more neurological manifestation of seizure, irritability, somnolence, coma, myasthenia, hypomyotonia, paralysis, and unconsciousness were considered as CNS involvement. Their clinical data were subjected to further analyses.
Cranial magnetic resonance imaging (MRI) was performed on 160 patients of total 179 patients investigated. The imaging evidence of pathological CNS alteration included white matter signal changes, cerebral volume loss, edema, enlargement of ventricles, and intracerebral calcification.
Lumbar punctures were performed in 117 patients to detect the leukocytes and protein content in cerebrospinal fluid (CSF). Leukocyte number above 19 × 10 9 /L or total protein concentration above 500 mg/L in CSF was regarded as abnormal. [15] 
Therapeutic regimen
Once patients were diagnosed as HLH, they were immediately received HLH-94/04 protocol. After the causes were determined, they were given the corresponding etiological treatment. For the CNS-HLH patients, intrathecal injections were performed based on the HLH-94/04 protocol. [14] 
Statistical analysis
Median and range of the data, which did not conform to a normal distribution, were displayed. GraphPad Prism 5 statistical analysis software (GraphPad Software, Inc., CA, USA) was used. The two-tailed Chi-squared test was applied to compare constituent ratio between different groups. A value of P < 0.05 was considered to denote a significant difference. Kaplan-Meier survival curves were used to analyze the overall survival (OS) of HLH patients.
Results
Patients
We divided the total 179 patients into three groups (FHL, EBV-sHLH, and other sHLH). Detailed information about the patients is shown in Table 1 . In total, 19 (10.6%) of 179 patients had familial HLH. The mean age was 2.80 ± 0.67 years (range: 5 months to 9.6 years), and the median age was 1.4 years. Of 179 patients, 97 (54.2%) were 
Neurological symptoms
HLH patients always have involvement of multiple tissues and organs, including hematology system, cardiovascular system, respiratory system, and urology system. In this study, 38 (21.2%) of 179 HLH children had CNS symptoms, regardless of their subgroups of HLH. Among them, nine (23.7%) patients were diagnosed as FHL, 14 (36.8%) as EBV-sHLH, and the rest 15 (39.5%) as other sHLH. Neurological complications included seizures, irritation, somnolence, coma, myasthenia, hypomyotonia, paralysis, and unconsciousness. Irritation was the most common CNS manifestation and found in 23 (50.5%) of 38 children. Seizure of general or focal nature was involved in 15 (39.5%) of 38 patients, and unconsciousness or coma was seen in 11 (28.9%) of 38 children. Other neurological complications included drowsiness (8/38, 21.1%), hypotonia or hypomyotonia (5/38, 13.2%), positively pathological reflex (5/38, 13.2%), cranial nerve palsy (3/38, 7.9%), and meningitis (2/38, 5.3%). A total of 20 (52.6%) patients of the 38 patients with CNS symptoms had more than one abovementioned clinical presentations.
Regarding the percentage of CNS symptoms in different HLH patients, 47.4% (9/19) of children had neurological symptoms in FHL group, higher than that in EBV-sHLH group (14.4%, 14/97, χ 2 = 10.840, P = 0.001) or in other sHLH group (23.8%, 15/63, χ 2 = 3.914, P = 0.048) [ Table 2 ]. In summary, neurological symptoms were found more frequently in patients with FHL, rather than those in EBV-sHLH and other sHLH groups. Significant differences could be found among these three groups ( χ 2 = 10.690, P = 0.005) [ Table 2 ]. Table 2 ]. However, the fact that six out of ten patients with imaging changes in FHL group had extensive and multifocal changes in white matter implied that FHL patients were prone to have severe changes in CNS. To be noted, the proportions of patients with altered radiological findings were higher than those with CNS symptoms in all three groups. This indicates that imaging abnormalities are not equivalent to clinical presentation in HLH children, regardless of FHL, EBV-sHLH, or other sHLH.
Neurological imaging findings
Cerebrospinal fluid
Lumbar punctures were performed in 116 HLH patients to detect CSF content, including white blood cell (WBC) number as well as total protein concentration. Of 12 FHL children, 7 (58.3%) presented changes in CSF. By contrast, only three (4.8%) of all 63 EBV-sHLH patients subjected to lumbar punctures exhibited abnormal CSF. In other sHLH group, abnormal CSF results were found in seven (17.1%) of 41 children [ Table 2 ]. These results revealed that CSF abnormality is more closely associated with FHL patients, but not the EBV-sHLH patients, which showed lowest ratio of abnormal CSF. Significant differences could be found in the three groups ( χ 2 = 23.430, P < 0.0001) [ Table 2 ]. In these 17 patients who had abnormal CSF results, 13 (76.5%) only had increased protein level, two patients (11.8%) only had increased WBC number, and the remaining two (11.8%) children had both abnormalities. 
Prognosis
Except for 17 patients who were failed to follow-up, 162 cases were investigated until March 31, 2017, and 117 of them were alive at that time.
Abnormalities in one or more of CNS symptoms, radiological findings, and CSF were regarded as CNS involvement. Excluding the cases lost to follow-up and with incomplete data, 3-year probable OS was 68.9% ± 4.9% (62/90) in the group of CNS involvement, which was obviously lower than that in patients without CNS involvement (86.0% ± 4.6%, 49/57; hazard ratio [HR] = 2.286, P = 0.019) [ Table 3 and Figure 1a ]. Thus, we need to figure out which factors in these three factors (CNS symptoms, imaging findings, and CSF) were more important to influence prognosis.
Based on the CNS symptoms, 15 children with neurological symptoms were dead, but 22 were alive (one failed to follow-up). On the other hand, 30 of 125 patients without CNS clinical manifestations were dead. The 3-year probable OS of children with neurological symptoms (59.5% ± 8.1%) was lower than those without CNS symptoms (76.0% ± 3.8%; HR = 2.147, P = 0.047) [ Table 3 and Figure 1b ]. In addition, among the 15 patients with seizure, eight were alive, and the 3-year OS was 53.3%; among the 11 patients with coma, five were alive, and the 3-year OS was 45.5%; there were six patients with both seizure and coma, and the 3-year OS was 50.0% ± 17.2% (three of them were alive).
In the group of 76 children with abnormal imaging findings, 56 children were alive. In the other group of 71 patients without MRI changes, 58 patients were alive. The 3-year probable OS were 73.7% ± 5.1% (with imaging changes) and 81.7% ± 4.6% (without imaging changes), respectively, with no statistical difference (HR = 0.657, P = 0.244) [ Table 3 and Figure 1c] . However, patients with extensive and multifocal white matter signal abnormalities in T2-weighted images showed a lower 3-year OS of 50% ± 15.8% (5/10) compared with those who only had punctuate or focal changes or without changes (79.6% ± 3.5%, 109/137, HR = 0.208, P = 0.033).
In a group of 17 patients with abnormal CSF, 11 (64.7% ± 11.6%) were alive. In the normal CSF group, 80/94 (85.1% ± 3.7%) were alive. And, the difference was statistically significant (HR = 0.255, P = 0.038) [ Table 3 and Figure 1d ].
Among FHL, EBV-HLH, and other-sHLH groups, no significant difference could be found in their OS (P = 0.257). This might be contributed to the limited cases in FHL group, and more patients should be collected to analyze more accurately.
dIscussIon
The study showed that CNS involvement was an important risk factor for HLH patients, and CNS symptoms might be the most important prognostic factor in CNS involvement. It was reported that neurological symptoms could be seen in the range from 10% to 38% of HLH patients. [12, 13, [16] [17] [18] According to our conclusions and other reports, irritability and seizure were the two most frequent CNS symptoms. [13, 15, 18] Moreover, we noticed that HLH patients with seizure or coma had the worst prognosis. Doctors should pay more attention to these HLH patients who have CNS symptoms, especially those with coma or seizure. Early treatments with focus on CNS involvement and stem cell transplantation are needed to improve their prognosis.
Both previous study and our results showed that white matter signal changes and cerebral volume loss are the two most frequent abnormalities in HLH patients with CNS involvement. [19] However, no changes in MRI could be considered as a specific manifestation of HLH so far. [20, 21] These changes can also be found in some other demyelinating diseases, such as multiple sclerosis and acute disseminated encephalomyelitis. If a patient has cerebral white matter signal changes in T2-weighted images accompanied with fever, splenomegaly, cytopenia, or elevated liver enzymes, HLH with CNS involvement should be considered. Serum ferritin, triglyceride, fibrinogen, NK cell activity, sCD25, and bone marrow smear should be tested to confirm or exclude the diagnosis of HLH with CNS involvement. Although there are no specific changes in imaging findings till now, we discovered that extensive and multifocal changes in white matter often indicated worse prognosis in HLH patients. Furthermore, we found that MRI image changes could be partially reversed in 63.8% (51/80) patients after treatment (especially in EBV-sHLH patients). It was not easy for the abnormalities to return to normal (7.5%, 6/80).
We also found that increased CSF protein level was the main abnormality and contributed to a bad prognosis in former study. [18] We have not found any specific change in the CSF results of HLH patients yet. Thus, we must differentiate other diseases carefully, such as CNS infection and autoimmune CNS disorder. We found that once HLH patients had both CNS symptoms (especially coma) and abnormal CSF (especially increased protein level), they would have worse prognosis.
Pediatric FHL patients always show worse outcome compared with those with secondary HLH. Interestingly, in this retrospective study, we found that FHL patients with CNS symptoms all had abnormal imaging findings, whereas 55 of 80 sHLH patients with abnormal cranial imaging performance did not have CNS clinical manifestations. This suggested that abnormal cranial imaging could occur earlier than CNS clinical manifestations. Thus, all HLH patients should take the MRI examination, regardless whether they have CNS symptoms or not.
In regard to treatment, CNS involvement is not an isolated disease itself, but a part of a systemic inflammatory response, predicting a worse outcome. Thus, in this study, we chose HLH-2004 protocol with intrathecal treatment as a standard care or first-line therapy to treat patients with CNS involvement. [14, 21] As reports showed that dexamethasone has a longer half-life and better CSF penetration than prednisone, we injected intrathecal with dexamethasone. In the 17 patients with abnormal CSF, 14 of them reexamined CSF after 4 weeks and 85.7% (12/14) returned to normal, which was similar with a latest study. [22] Besides, hematopoietic stem cell transplantation (HSCT) was performed in eight patients and seven (87.5%) of them had long survivals. In this study, five out of seven patients got improvements in cerebral MRI images after HSCT. In all, early HSCT after well control of HLH status is necessary for HLH patients with CNS involvement. [23] However, there are also some limitations in this study. For example, in the other HLH group, the primary diseases were variables, including infections caused by other agents such as CMV, HSV, or Leishmania major; hematologic malignancies such as leukemia, lymphoma, and LCH; autoimmune or autoinflammatory disorders such as systemic lupus erythematosus, systemic juvenile idiopathic arthritis, and scleroderma; and some uncertain causes. It had been known that different protopathies might lead to different outcomes. In this study, there were five patients with lymphoma, and two of them were dead. There were two acute myeloid leukemia-related HLH patients: one was dead and the other with whom we lost contact. Patients with connective tissue disease seemed to show a better prognosis in another research (unpublished) which need to accumulate more data. In our following study, more cases should be included to analyze the OS according to different primary diseases.
Moreover, HLH always impairs multiple tissues and organs, not only CNS but also digestive system, respiratory system, and immune system. Therefore, many laboratory examinations could be found such as increased liver enzyme, ferritin, inflammatory medium and triglyceride, and decreased fibrinogen. It is well known that HLH is a systematic inflammatory disease, but the pathogenic mechanism of CNS susceptibility is unclear. There is a question that whether there are some correlations between these abnormal laboratory results and CNS involvement. It is difficult to conclude based on the limited data, and improved study should be performed in the future.
In summary, we find that HLH children with CNS involvement always have worse outcomes than those without CNS involvement. CNS symptoms (especially coma) and extensive and multifocal white matter changes in MRI and abnormal CSF results are found having more significance to the prognosis. FHL patients are prone to have CNS involvement and show the poorest outcome, compared with EBV-sHLH and other sHLH groups. Systemic treatment of HLH and intrathecal injection with methotrexate and corticosteroids is still first-line treatment of HLH with CNS involvement. Early HSCT after keeping HLH status in control is strongly recommended for HLH patients with CNS involvement.
